Is NMN Supplementation Really Safe for Dogs? New Experimental Data Puts the Debate to Rest!
While we are deeply engaged in exploring anti-aging solutions for humans, our furry companions at home are quietly facing health challenges brought on by aging—reduced energy levels, dull coats, and a slower metabolism. As responsible pet owners, we naturally want to do everything possible to safeguard their health.
In recent years, the popular anti-aging ingredient NMN (Nicotinamide Mononucleotide) has attracted widespread attention. But can it truly serve as an “anti-aging weapon” for pet dogs? This question has long been surrounded by controversy.
Recently, a research team from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, published a groundbreaking study in the authoritative journal Frontiers in Pharmacology. Backed by rigorous experimental data, the study provides a clear answer: NMN demonstrates outstanding safety in dogs, offering solid scientific support for pet anti-aging applications.
PART 01
A High-Standard Study: Revealing the True Safety Profile of NMN in Dogs
To thoroughly evaluate the safety of NMN in large mammals, the research team designed a highly targeted and scientifically rigorous experiment. From subject selection to testing methodologies, every aspect was carefully controlled.
The study involved 10 healthy Beagle dogs at the prime stage of life—around 4 years old, weighing 9–11 kg, which corresponds to a common “middle-aged” stage in pet dogs. The dogs were randomly divided into two groups:
Throughout the study, researchers conducted comprehensive, 360-degree monitoring, including:
PART 02
Robust Results: NMN Safety Exceeds Expectations
The 14-day monitoring results were clear and consistent: NMN demonstrated excellent safety. All Beagle dogs receiving NMN showed normal health status, with no abnormal reactions observed. The safety of NMN fully withstood rigorous testing.
PART 03
Significant Scientific Implications: Opening a New Chapter in Pet Anti-Aging
The importance of this study goes far beyond simply confirming NMN’s safety. As a large mammal, Beagle dogs share many physiological and metabolic similarities with humans. Therefore, this research not only fills a critical gap in safety evaluations of NMN in large animal models such as pet dogs, but also provides valuable reference data for future human applications.
The study’s daily dosage of 1,340 mg far exceeds typical supplemental levels. Even at this extreme dose, only mild and reversible effects were observed, highlighting NMN’s wide safety margin. This lays a solid foundation for future research into appropriate daily dosages and long-term supplementation effects in dogs, while giving pet owners greater scientific confidence when considering NMN products.
As scientific research continues to advance, NMN is expected to become one of the scientifically supported options for promoting healthy aging in pets. As a pioneer in the NMN field, Bontry Bio remains closely aligned with cutting-edge scientific research, committed to transforming rigorous science into safe, reliable products—helping pets enjoy healthier, higher-quality lives in their later years.
In recent years, the popular anti-aging ingredient NMN (Nicotinamide Mononucleotide) has attracted widespread attention. But can it truly serve as an “anti-aging weapon” for pet dogs? This question has long been surrounded by controversy.
Recently, a research team from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, published a groundbreaking study in the authoritative journal Frontiers in Pharmacology. Backed by rigorous experimental data, the study provides a clear answer: NMN demonstrates outstanding safety in dogs, offering solid scientific support for pet anti-aging applications.
PART 01
A High-Standard Study: Revealing the True Safety Profile of NMN in Dogs
To thoroughly evaluate the safety of NMN in large mammals, the research team designed a highly targeted and scientifically rigorous experiment. From subject selection to testing methodologies, every aspect was carefully controlled.
The study involved 10 healthy Beagle dogs at the prime stage of life—around 4 years old, weighing 9–11 kg, which corresponds to a common “middle-aged” stage in pet dogs. The dogs were randomly divided into two groups:
- Experimental group: received an oral saturated NMN solution twice daily
- Control group: received an equivalent amount of water
Throughout the study, researchers conducted comprehensive, 360-degree monitoring, including:
- Daily behavior, activity levels, and mental status
- Coat condition and general appearance
- Vital signs such as respiration and heart rate
- Advanced serum biochemical analyses
- Histopathological examinations
- Quantitative metabolite measurements
PART 02
Robust Results: NMN Safety Exceeds Expectations
The 14-day monitoring results were clear and consistent: NMN demonstrated excellent safety. All Beagle dogs receiving NMN showed normal health status, with no abnormal reactions observed. The safety of NMN fully withstood rigorous testing.
Observable Health Indicators
Dogs in the NMN group displayed:- Normal activity and lively behavior
- Bright eyes and glossy, smooth coats
- No diarrhea, vomiting, lethargy, or other adverse symptoms
Objective Physiological Data Further Confirm Safety
- Efficient metabolic absorption:
Serum levels of nicotinamide (an active metabolite of NMN) increased significantly in the NMN group (p < 0.000001), confirming effective absorption and metabolic conversion in dogs. - Stable liver and kidney function:
Key liver enzymes—AST (aspartate aminotransferase) and ALT (alanine aminotransferase)—as well as blood urea nitrogen, a critical kidney function marker, showed no significant differences compared with the control group. Histopathological analysis of liver and kidney tissues revealed normal morphology with no signs of pathological damage. - Normal lipid metabolism:
Blood lipid parameters, including total cholesterol, triglycerides, HDL-C, and LDL-C, were comparable between the two groups, with no abnormal elevations or reductions observed. - Only mild and reversible changes:
Slight increases in creatinine and uric acid were observed but remained within safe ranges and had no meaningful impact on overall health. These changes were considered mild and acceptable.
PART 03
Significant Scientific Implications: Opening a New Chapter in Pet Anti-Aging
The importance of this study goes far beyond simply confirming NMN’s safety. As a large mammal, Beagle dogs share many physiological and metabolic similarities with humans. Therefore, this research not only fills a critical gap in safety evaluations of NMN in large animal models such as pet dogs, but also provides valuable reference data for future human applications.
The study’s daily dosage of 1,340 mg far exceeds typical supplemental levels. Even at this extreme dose, only mild and reversible effects were observed, highlighting NMN’s wide safety margin. This lays a solid foundation for future research into appropriate daily dosages and long-term supplementation effects in dogs, while giving pet owners greater scientific confidence when considering NMN products.
As scientific research continues to advance, NMN is expected to become one of the scientifically supported options for promoting healthy aging in pets. As a pioneer in the NMN field, Bontry Bio remains closely aligned with cutting-edge scientific research, committed to transforming rigorous science into safe, reliable products—helping pets enjoy healthier, higher-quality lives in their later years.
